|Day Low/High||138.86 / 140.14|
|52 Wk Low/High||118.62 / 148.99|
Icahn may have a tough time finding interest in this behemoth.
Every single market indicator I look at is overbought. But it's likely that shorts and underperformers are buoying stocks. Some are at the most overbought in decades. The bond market is clearly not as sanguine on economic growth/corporate profi...
Integra hopes this deal will grow its revenue to $2 billion sooner than expected.
Amazon, J&J, IBM and others don't deserve this treatment.
They have become a referendum on Trump's plans for lower corporate taxes.
"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...
J&J has the potential to 'blow out' Actelion's high blood pressure drug, says Jim Cramer.
Johnson & Johnson is buying the Swiss biotech Actelion for $30 billion.
Johnson & Johnson plans to spin out Actelion's research and development unit into a separate business.
The most logical path for Johnson & Johnson in the next 12 months appears to be sideways or down.
Too many traders overthink market action rather than embrace the momentum and look for reasons to enjoy the upside.
The Dow Jones Industrial Average took almost 103 years to reach 10,000 in March 1999 and nearly 18 more years to reach 20,000.
I'd like to see confirmation of this reversal tomorrow, but now I would "stick my neck out" and write puts.
Half the Dow components have reported and it's their impressive results that are driving indices up.
Jim Cramer says the Dow hitting 20,000 is different from previous big runs because the milestone comes during earnings season and allows traders to reevaluate.
The Dow Jones Industrial Average sports double-digit gains for the first time in three weeks, moving it closer to 20,000.
Today's market has ignored disappointing profit results at 3M (down $3), Johnson & Johnson (down $3) and Verizon (down $2.50), among others. The "reflation" trade appears to be back (in part a function of several predictable executive orders by ...
Jim Cramer thought Johnson & Johnson's results were decent but he remains cautious on pharma.
Johnson & Johnson posted better-than-expected fourth-quarter 2016 earnings amid lower 2017 forecasts.
The following companies (hat tip Zero Hedge) missed on the top line (sales) this morning (profits weren't much better): Johnson & Johnson MMM DuPont Kimberly-Clark Verizon Again, for emphasis -- beware of the bullish narrative of an improving profit...
Dow Jones Industrial Average member Johnson & Johnson is lower in pre-market trading. The reason? The drug maker took a page out of IBM's playbook by recording a much lower effective tax rate in the quarter (14.5% vs. 18%), which on an adjusted basi...
On Tuesday, January 24, investors await a host of quarterly earnings reports.
For the week of January 23, investors will be watching Donald Trump's first full week as President of the United States.
I had my most active day of the year trading. It was also my most profitable. Regardless of one's market view, I continue to see more opportunities on the trading side vs. the investing side in the months ahead. I started the day with a story re...
After an up-and-down year, this household name is as strong as ever.